Ensuring Patient Safety: FDA’s Draft Guidance on Assessing Overall Survival in Oncology Clinical Trials — A Multi-Perspective Analysis
Article 1. Regulatory Perspective The FDA’s August 2025 draft guidance outlines recommendations for evaluating Overall Survival (OS) in randomized oncology trials, particularly when OS isn’t the primary endpoint U.S. Food and Drug Administration. 2. Pharmacovigilance Perspective OS serves not only as efficacy but a critically objective safety endpoint. 3. MAH (Marketing Authorization Holder) Perspective From […]
Empowering Safe Innovation: FDA’s Predetermined Change Control Plan (PCCP) Guidance for AI-Enabled Medical Device Software Functions – A Regulatory, Pharmacovigilance, MAH, and Impact Perspective
1. Regulatory Perspective In April 2023, the FDA issued draft guidance introducing the Predetermined Change Control Plan (PCCP) framework. Its goal: to enable AI/ML-enabled device software functions (AI-DSFs) to be updated safely, effectively, and more swiftly, without requiring new submissions for each iteration Data Matters Privacy BlogU.S. Food and Drug Administration. These adjustments reflect the […]
FDA warns against unapproved epinephrine nasal solutions from BPI Labs & Endo USA: what happened, why it matters, and what to do now
Key takeaways What the FDA alert actually says On Jan 16, 2025, the FDA told health care professionals not to use unapproved epinephrine nasal solutions from BPI Labs and Endo USA because they’re being mistaken for injectable epinephrine. The agency emphasized that the nasal products are not sterile, so any IV administration could cause infection […]
FDA Warning Letter to Vacation, Inc. (Aug 6, 2025): What Happened, Why It Matters, and What Comes Next
On August 6, 2025, the FDA issued a Warning Letter to Vacation, Inc. over its “Classic Whip” sunscreens sold in mousse/whipped-cream style canisters. The agency says these products are misbranded and illegally marketed because the foam dosage form isn’t permitted under today’s OTC sunscreen rules—and because the packaging closely resembles edible whipped cream, creating a […]
Syfovre (pegcetacoplan) — “Slowing the Fade: The First Approved Drug to Slow Geographic Atrophy — Promise, Patents, and Problems”
Below is an in-depth, evidence-based article on Syfovre (active substance pegcetacoplan) that covers: developer and regulatory status, the IP/patent picture, the drug’s benefits, limitations, and the main safety concerns that arose in clinical trials and post-marketing. Key source material is the EMA EPAR/CHMP pages, the OAKS and DERBY Phase-3 trials, Apellis product information, and regulatory […]
Comirnaty — “mRNA on the Frontline: How Tozinameran Changed Vaccination”
Executive summary (one line) Comirnaty (tozinameran, BNT162b2) is the Pfizer–BioNTech mRNA COVID-19 vaccine that transformed pandemic response through very high clinical efficacy, rapid global rollout, and an adaptable mRNA platform — but it brought a complex patent landscape and rare, important safety signals (notably myocarditis/pericarditis and allergic reactions) that regulators continue to monitor. European Medicines […]
Imjudo (tremelimumab) — “Turning up the Heat on Cancer: The Promise and Price of CTLA-4 Blockade”
Below is an in-depth, evidence-based article about Imjudo (active ingredient tremelimumab): who developed it, the intellectual-property picture, clinical benefits, limitations, and the main safety signals that emerged during trials and post-marketing. Key source material is the EMA EPAR/assessment report and major regulatory/clinical reviews (cited after the most important statements). Quick summary (TL;DR) Imjudo (tremelimumab) is […]
Nintedanib Accord: Europe’s First Generic Nintedanib—What to Know About Origins, Patents, Benefits, Risks, and Trial Safety
Short take: Nintedanib Accord is the EU-authorised generic of Boehringer Ingelheim’s nintedanib (brand: Ofev). It slows lung-function decline across several fibrosing interstitial lung diseases (ILDs). Its biggest upsides are consistent efficacy across IPF, progressive-phenotype ILDs, and SSc-ILD, plus an oral regimen and now a lower-cost generic option. The trade-offs are predictable: frequent GI side-effects (especially […]
Keytruda (pembrolizumab): a deep-dive
What it is. Keytruda is Merck & Co.’s (MSD outside the US/Canada) humanized IgG4 monoclonal antibody that blocks PD-1, releasing an immune “brake” so T-cells can attack cancer. In the EU it’s authorized—alone and in combinations—across a very broad slate of tumors (NSCLC, melanoma, RCC, urothelial, HNSCC, MSI-H/dMMR cancers, gastric/GEJ, oesophageal, cervical, TNBC, biliary tract, […]